Update shared on 20 Nov 2025
Fair value Decreased 4.39%Analysts have revised their price target for Dynavax Technologies downward from $22.80 to $21.80. They cite slight adjustments to key financial assumptions, including discount rate, revenue growth, and profit margin forecasts.
What's in the News
- Dynavax Technologies announced a share repurchase program, planning to buy back up to $100 million of common stock. Execution is expected over the next year (Company filing).
- The company reiterated its 2025 earnings guidance and anticipates HEPLISAV-B net product revenue between $315 million and $325 million (Company guidance).
- Dynavax presented positive topline data from a Phase 1/2 clinical trial for its Z-1018 shingles vaccine candidate. The company also initiated the second part of the trial, enrolling adults 70 years and older (Clinical announcement).
- The Board of Directors authorized a buyback plan in October 2025 (Board resolution).
Valuation Changes
- Consensus Analyst Price Target has decreased slightly from $22.80 to $21.80.
- Discount Rate has risen modestly from 7.08% to 7.35%.
- Revenue Growth projection has edged down from 15.47% to 15.21%.
- Net Profit Margin forecast has declined marginally from 26.28% to 26.10%.
- Future P/E Ratio estimate has fallen from 20.57x to 20.24x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.